View from Brussels

Jul 01, 2002
Applied Clinical Trials
By Applied Clinical Trials Editors
The European Union is working to develop pediatric rules to ensure that medicines prescribed for children are safe, effective, and of high quality.
Jun 01, 2002
Applied Clinical Trials
By Applied Clinical Trials Editors
EU proposals are finally available for the pharmaceutical industry to begin commenting on, and you can bet the industry will take advantage of it.
May 01, 2002
Applied Clinical Trials
By Applied Clinical Trials Editors
A new guideline details basic requirements for submitting a successful application for a proposed orphan drug in the European Union.
Apr 01, 2002
Applied Clinical Trials
By Applied Clinical Trials Editors
With the impending expansion of the EU and the revamping of current policies, the pharmaceutical industry is on edge, wanting to know what the future holds.
Feb 01, 2002
Applied Clinical Trials
By Applied Clinical Trials Editors
To help protect patient safety and cut red tape, the European Union is working to create tougher standards of pharmacovigilance.
Jan 01, 2002
Applied Clinical Trials
By Applied Clinical Trials Editors
European Parliament debates on the allocation of research funds reveals Euro-MPs views of clinical research in medicines development.
Nov 01, 2001
Applied Clinical Trials
By Applied Clinical Trials Editors
A high-level group explores ways to support EU pharmaceutical industry research without too much cost to the EU health agencies that pay for medicines.
Oct 01, 2001
Applied Clinical Trials
By Applied Clinical Trials Editors
The EU?s Committee for Proprietary Medicinal Products describes the process clinical investigations should follow.
Sep 01, 2001
Applied Clinical Trials
By Applied Clinical Trials Editors
Patients, research companies, and regulatory authorities may all benefit from proposed changes to current pharmaceutical legislation, but the proposals will provoke much debate.
Aug 01, 2001
Applied Clinical Trials
By Applied Clinical Trials Editors
The EMEA updates its positions on placebos, Crohn?s disease trials, and postmarketing surveillance of drugs used by pregnant women.
native1_300x100
lorem ipsum